Baricitinib shows promise for treating alopecia areata with mild side effects.
6 citations
,
December 2018 in “Ophthalmic Plastic and Reconstructive Surgery” Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
2 citations
,
December 1997 in “Journal of The American Academy of Dermatology” The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.
13 citations
,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
1 citations
,
December 2021 in “JAAD case reports” A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
October 2024 in “Journal of the Endocrine Society” Type B Insulin Resistance Syndrome is rare, linked to lupus, and hard to treat due to severe insulin resistance.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
1 citations
,
January 2023 in “Cutis” You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
4 citations
,
January 2025 in “JAAD reviews.” Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia”
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
Baricitinib may not always prevent relapse in alopecia areata.
20 citations
,
January 2016 in “Intractable & Rare Diseases Research” Combination therapy, especially with finasteride, is effective for treating frontal fibrosing alopecia.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
3 citations
,
June 2025 in “Archives of Dermatological Research” Stopping TNFα inhibitors can help children regrow hair lost due to the medication.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.